Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, China; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou City, Guangdong Province, China.
Chest. 2021 Aug;160(2):754-764. doi: 10.1016/j.chest.2021.03.022. Epub 2021 Mar 18.
Visceral pleural invasion (VPI) with PL1 or PL2 increases the T classification from T1 to T2 in non-small cell lung cancers (NSCLCs) ≤ 3 cm. We proposed a modified T classification based on VPI to guide adjuvant therapy.
Is it reasonable to upstage PL1-positive cases from T1 to T2 for NSCLCs ≤ 3 cm?
In total, 1,055 patients with resected NSCLC were retrospectively included. Tumor sections were restained with hematoxylin and eosin stain and Victoria blue elastic stain for the elastic layer. Disease-free survival (DFS) and overall survival (OS) were calculated by the Kaplan-Meier method. Subgroup analysis and a Cox proportional hazards model were used to further determine the impact of VPI on survival.
The extent of VPI was diagnosed as PL0 in 824 patients, PL1 in 133 patients, and PL2 in 98 patients. The 5-year DFS rates of patients with PL0, PL1, and PL2 were 62.6%, 60.2%, and 28.8% (P < .01), whereas the corresponding 5-year OS rates were 78.6%, 74.4%, and 50.0% (P < .01), respectively. As predicted, the DFS and OS of patients with PL2 were much worse than those of patients with PL0 (P < .01) and PL1 (P < .01). However, both the DFS and OS of patients with PL0 and PL1 were comparable (DFS: P = .198; OS: P = .150). For node-negative cases, the DFS and OS of patients with PL0 and PL1 were also comparable (DFS: P = .468; OS: P = .388), but patients with PL2 had much worse DFS and OS than patients with PL0 (P < .01) and PL1 (P < .01). Multivariable analyses suggested that PL2, together with node positivity and poor cell differentiation, was an independent adverse prognostic factor.
In NSCLCs ≤ 3 cm, tumors with PL1 should remain defined as T1, not T2. Overtreatment by adjuvant chemotherapy in node-negative NSCLCs ≤ 3 cm might be avoided in PL1 cases.
在直径 ≤ 3cm 的非小细胞肺癌(NSCLC)中,有脏层胸膜侵犯(VPI)且 PL1 或 PL2 阳性会将 T 分期从 T1 升级为 T2。我们提出了一种基于 VPI 的改良 T 分期,以指导辅助治疗。
将 PL1 阳性的直径 ≤ 3cm 的 NSCLC 病例从 T1 升级为 T2 是否合理?
共纳入 1055 例接受 NSCLC 切除术的患者。肿瘤切片用苏木精-伊红染色和维多利亚蓝弹力纤维染色重新染色,以观察弹力层。通过 Kaplan-Meier 法计算无病生存率(DFS)和总生存率(OS)。进行亚组分析和 Cox 比例风险模型,以进一步确定 VPI 对生存的影响。
824 例患者的 VPI 程度诊断为 PL0,133 例为 PL1,98 例为 PL2。PL0、PL1 和 PL2 患者的 5 年 DFS 率分别为 62.6%、60.2%和 28.8%(P<0.01),相应的 5 年 OS 率分别为 78.6%、74.4%和 50.0%(P<0.01)。正如预测的那样,PL2 患者的 DFS 和 OS 明显差于 PL0(P<0.01)和 PL1(P<0.01)患者。然而,PL0 和 PL1 患者的 DFS 和 OS 相当(DFS:P=0.198;OS:P=0.150)。对于淋巴结阴性病例,PL0 和 PL1 患者的 DFS 和 OS 也相当(DFS:P=0.468;OS:P=0.388),但 PL2 患者的 DFS 和 OS 明显差于 PL0(P<0.01)和 PL1(P<0.01)患者。多变量分析表明,PL2 与淋巴结阳性和低分化一起是独立的不良预后因素。
在直径 ≤ 3cm 的 NSCLC 中,PL1 阳性肿瘤仍应定义为 T1,而非 T2。在 PL1 病例中,淋巴结阴性直径 ≤ 3cm 的 NSCLC 可能避免辅助化疗过度治疗。